The present review focuses on pathogenic molecular and transcriptional events in patients with lupus nephritis. These factors are renal DNaseI, exposed chromatin fragments and the corresponding chromatin-reactive autoantibodies. Lupus nephritis is the most serious complication in human systemic lupus erythematosus, and is characterised by deposition of chromatin fragment-IgG complexes in the mesangial matrix and glomerular basement membranes. The latter deposition defines end-stage disease. This event is stringently linked to a renal-restricted shutdown of expression of the DNaseI gene, as determined by loss of DNaseI mRNA level and DNaseI enzyme activity. The major aim of the present review is to generate new therapeutic strategies based on new insight into the disease pathogenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132027 | PMC |
| http://dx.doi.org/10.1186/ar3281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TLR7 responses in glomerular macrophages accelerate the progression of glomerulonephritis in NZBWF1 mice.
Int Immunol
January 2025
Division of Innate Immunity, The Institute of Medical Science, The University of Tokyo; Minato-ku, Tokyo 108-8639, Japan.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies and damage to multiple organs. Glomerulonephritis, a manifestation involving glomerular deposition of immune complexes and complement components, significantly contributes to disease morbidity. Although the endosomal single-stranded RNA sensor TLR7 is known to drive glomerulonephritis by promoting autoantibody production in B cells, the contribution of macrophage TLR7 responses to glomerulonephritis remains poorly understood.
View Article and Find Full Text PDFClinical Characteristics, Microbiological and Risk Factors of Infections in Patients With Systemic Lupus Erythematosus.
J Community Hosp Intern Med Perspect
January 2025
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Objective: To determine risk factors, clinical and microbiological characteristics of infections in a single-center systemic lupus erythematosus (SLE) cohort.
Methods: All hospital patients in The First Affiliated Hospital of Zhengzhou University from 2019 to 2021 who meet ≥4 ACR-97 SLE criteria were identified. Patients with infection and without infection were included with a ratio of 1:2.
Organ Damage and Its Associated Factors in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study.
J Clin Med Res
January 2025
Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Background: Systemic lupus erythematosus (SLE) can affect a plethora of organ systems and cause organ damage due to the disease process and medication toxicity, notably corticosteroids. Patients with SLE often suffer irreversible organ damage. Older age, glucocorticoid use, longer disease duration, and disease activity all represent risk factors for organ damage.
View Article and Find Full Text PDFNew Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis.
J Clin Med
January 2025
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus, affecting roughly 40% of all lupus patients. With the introduction of cyclophosphamide and mycophenolate mofetil, outcomes have dramatically improved. However, 10% of patients still progress towards end-stage kidney disease, which carries an elevated mortality rate.
View Article and Find Full Text PDFSafety Profile of SARS-CoV-2 Vaccination in Patients with Lupus Nephritis: A Retrospective Study.
J Clin Med
January 2025
Division of Nephrology, 2nd Department of Internal Medicine, Attikon University Hospital, School of Health Sciences, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Vaccination against SARS-CoV-2 has been vital in alleviating the spread of the recent pandemic. We aimed to estimate the frequency and type of adverse events related to SARS-CoV-2 vaccine in patients with lupus nephritis (LN), and assess its impact, if any, on the risk of subsequent reactivation of nephritis. This was a retrospective, multicenter study which included patients with biopsy-proven LN, who had received at least one vaccine dose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!